In-vitro thrombogenicity assessment of flow diversion and aneurysm bridging devices

Endoluminal devices such as metallic flow diversion (FD) and aneurysm bridging (AB) stents are used for treatment of intracranial aneurysms. Treatments are associated with thrombogenic events mandating the use of dual antiplatelet therapy in all cases. In the current in vitro study, we utilize a slow binding fluorogenic thrombin specific substrate to measure the thrombin generation potential of six devices: four FD devices (Pipeline (TM) Flex embolization device, Pipeline (TM) Flex embolization device with Shield Technology (TM), SILK+, FRED (TM)) and two AB devices (Solitaire (TM) AB, LEO+). We show that the Pipeline (TM) Flex embolization device with Shield Technology (TM) has significantly lower peak thrombin and takes significantly longer time to achieve peak thrombin (time to peak) compared to the other three FD devices (p < 0.05), with statistically similar results to the less thrombogenic AB devices. We conclude that surface modification of endoluminal stents could be an effective method to mitigate thrombogenic complications.